Sygnature Discovery strengthens management team

4 September 2012

Nottingham-based Sygnature Discovery Limited has announced the appointment of Colin Sambrook Smith to the newly-created role of Head of Computational Chemistry and Informatics.

Simon Hirst, Sygnature’s Chief Executive Officer stated, “I am delighted to welcome Colin to Sygnature Discovery. He is a great addition to our management team. Colin is an experienced computational chemist and research manager with a proven ability to analyse and determine the scientific computing and information technology needs of research-based organisations.

"He has 26 years of R&D experience mostly within the pharmaceutical industry. Colin is already contributing his expertise into several on-going projects and is managing a new, fully-integrated drug discovery programme for a European biotech company.”

Colin Sambrook Smith added, “I am pleased to have joined Sygnature Discovery at a time when the company has been experiencing a huge increase in the demand for its integrated drug discovery services. Our customers are now mainly undertaking discovery projects which combine medicinal chemistry, computational chemistry and in vitro biology/screening at Sygnature, in vitro ADME at Cyprotex Discovery and pre-clinical experimental services at Saretius, or Pneumolabs through the ‘federated’ CRO model."


To top